BMYvsMRK
Bristol-Myers Squibb CovsMerck & Co Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Bristol-Myers Squibb Co
$59.02
+8.71%
Merck & Co Inc
$114.62
+15.57%
60-day price, rebased to 100
Round-by-round
Valuation upside
+2.90% vs -26.90% to DCF fair value
Balance-sheet strength
Altman Z 2.20 vs 4.02
Fundamental quality
Piotroski 9.00 vs 4.00 (of 9)
Growth + margins
Rule-of-40 26.40 vs 20.30
60-day momentum
+8.73% vs +1.10% price return
Market-cap liquidity
$117.4B vs $298.8B
Verdict
Across6categories,BMYtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onBMYorMRK
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.